Verici Dx Plc Market Cap ($42.35K)
Market Cap & Net Worth: Verici Dx Plc (VRCI)
Verici Dx Plc market cap. Verici Dx Plc (LSE:VRCI) has a market capitalization of $42.35K (GBX348.08 Million) as of November 4, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31702 globally and #1211 in its home market, demonstrating a 2.22% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Verici Dx Plc's stock price GBX0.23 by its total outstanding shares 1513394127 (1.51 Billion). Also see VRCI cash generation efficiency for how efficiently the company converts equity into cash flow.
Verici Dx Plc Market Cap History (2020–2026)
Verici Dx Plc market cap history from 2020 to 2026. Data shows change from $10.77 Million to $42.35K (-57.02% CAGR). Check Verici Dx Plc (VRCI) stock price for real-time trading data and today's change.
Index Memberships
Verici Dx Plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$998.29 Million | 0.00% | #416 of 722 |
Weight: Verici Dx Plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Verici Dx Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Verici Dx Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Verici Dx Plc net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.21x
Verici Dx Plc's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $1.80 Million | $1.01 Million | -$8.73 Million | 1.77x | N/A |
| 2024 | $713.53K | $3.34 Million | -$5.87 Million | 0.21x | N/A |
Competitor Companies of VRCI by Market Capitalization
Companies near Verici Dx Plc in the global market cap rankings as of November 4, 2026. Also see Verici Dx Plc (VRCI) total assets for a full breakdown of the balance sheet.
Key companies related to Verici Dx Plc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #143 globally with a market cap of $161.03 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #493 globally with a market cap of $54.62 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #539 globally with a market cap of $50.18 Billion USD ( CN¥342.92 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $682.65 |
| #143 | Danaher Corporation | NYSE:DHR | $161.03 Billion | $227.97 |
| #493 | Natera Inc | NASDAQ:NTRA | $54.62 Billion | $378.92 |
| #539 | WuXi AppTec Co Ltd | SHG:603259 | $50.18 Billion | CN¥138.65 |
Market Capitalization of Verici Dx Plc (2020–2026)
Market capitalization of Verici Dx Plc from 2020 to today. Between 2020 and today, Verici Dx Plc's market cap moved from $10.77 Million to $ 42.35K, with a yearly change of -57.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX42.35K | -68.28% |
| 2025 | GBX133.50K | -81.29% |
| 2024 | GBX713.53K | -60.26% |
| 2023 | GBX1.80 Million | -22.00% |
| 2022 | GBX2.30 Million | -75.49% |
| 2021 | GBX9.39 Million | -12.82% |
| 2020 | GBX10.77 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of Verici Dx Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $42.35K USD |
| MoneyControl | $42.35K USD |
| MarketWatch | $42.35K USD |
| marketcap.company | $42.35K USD |
| Reuters | $42.35K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Verici Dx Plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur… Read more